Latest News & Features
Careers
The firm’s Technology & Engineering team will be expanded with an expert in patent drafting, prosecution and opposition/defence work across AI, digital health and medical devices. 25 September 2025
Americas
A biotech firm specialising in mRNA therapies alleges AbbVie’s $2.1 billion Capstan purchase was built on stolen lipid nanoparticle trade secrets. 24 September 2025
Americas
As John Squires is confirmed as the US Patent and Trademark Office's new director, Sarah Speight gathers reaction, and asks: what would you ask the US’ chief IP executive? 23 September 2025
Americas
There are varying national eligibility requirements that distinguish between treatments of and diagnostics for animals and humans; it’s just a question of reformatting ‘method of treatment’ claims, write lawyers from Sterne Kessler. 23 September 2025
Americas
The pharma giant invalidates a university's patent while gaining FDA approval for a new subcutaneous version of Keytruda as it protects its $29.5-billion-a-year cancer drug ahead of a looming patent cliff. 22 September 2025
Careers
US firm’s new partner “brings a rare combination of scientific depth, global perspective, and strategic legal insight” to her new employer’s life sciences practice. 19 September 2025
Asia
At AIPPI’s World Congress 2025, a panel explored how personalised medicine is pushing patent law into new territory, and why harmonisation remains a distant goal. 18 September 2025
Careers
The exodus of patent trial litigators was ‘an easy choice’ due to their new employer’s ‘scale, vision and entrepreneurial culture’. 18 September 2025
Europe
A UPC Court of Appeal decision establishes a new benchmark for what constitutes imminent infringement in pharmaceutical patent litigation, particularly regarding generics’ pre-launch preparations, writes Mike Gruber of Carpmaels & Ransford. 18 September 2025
Europe
From trademark decisions to judicial writing, the IP community is embracing AI but questions loom about quality, precedents, and jurisdictional limits. Muireann Bolger reports from Marques’ annual meeting. 18 September 2025